MCID: MLN079
MIFTS: 46

Melanoma in Congenital Melanocytic Nevus

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Melanoma in Congenital Melanocytic Nevus

MalaCards integrated aliases for Melanoma in Congenital Melanocytic Nevus:

Name: Melanoma in Congenital Melanocytic Nevus 12
Melanocytic Nevi 12
Nevi Melanocytic 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0070327
NCIt 51 C48613

Summaries for Melanoma in Congenital Melanocytic Nevus

Disease Ontology : 12 A skin melanoma that arises from a congenital melanocytic nevus.

MalaCards based summary : Melanoma in Congenital Melanocytic Nevus, also known as melanocytic nevi, is related to melanoma and neurofibroma. An important gene associated with Melanoma in Congenital Melanocytic Nevus is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Pathways in cancer and MAPK-Erk Pathway. The drugs Triamcinolone and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, brain and lymph node, and related phenotypes are homeostasis/metabolism and integument

Related Diseases for Melanoma in Congenital Melanocytic Nevus

Diseases related to Melanoma in Congenital Melanocytic Nevus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 melanoma 30.5 BRAF MITF NRAS PMEL
2 neurofibroma 30.3 MITF S100B
3 vitiligo-associated multiple autoimmune disease susceptibility 1 30.3 MITF PMEL
4 amelanotic melanoma 30.2 BRAF S100B
5 acral lentiginous melanoma 30.0 BRAF NRAS
6 histiocytosis 30.0 BRAF S100B
7 skin melanoma 29.9 BRAF MITF NRAS PMEL
8 thyroid cancer, nonmedullary, 2 29.6 BRAF NRAS
9 melanoma, cutaneous malignant 1 29.3 BRAF MITF NRAS
10 langerhans cell histiocytosis 29.3 BRAF NRAS S100B
11 melanosis, neurocutaneous 11.9
12 giant congenital nevus 11.7
13 lentigines 11.6
14 melanocytic nevus syndrome, congenital 11.5
15 cutaneous mastocytoma 11.2
16 phacomatosis pigmentovascularis 11.2
17 mycosis fungoides 10.2
18 leukemia 10.2
19 dermatitis 10.2
20 epidermolysis bullosa 10.2
21 superficial spreading melanoma 10.2
22 epidermolytic hyperkeratosis 10.1
23 nevus, epidermal 10.1
24 dermatitis, atopic 10.1
25 basal cell carcinoma 1 10.1
26 severe cutaneous adverse reaction 10.1
27 epidermolysis bullosa dystrophica 10.1
28 basal cell carcinoma 10.1
29 skin carcinoma 10.1
30 mastocytosis 10.1
31 encephalitis 10.1
32 pyogenic granuloma 10.1
33 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.1
34 posterior uveal melanoma 10.1 BRAF MITF
35 gallbladder melanoma 10.1 MITF PMEL
36 vitiligo-associated multiple autoimmune disease susceptibility 6 10.0 MITF PMEL
37 myopericytoma 10.0 BRAF S100B
38 hermansky-pudlak syndrome 3 10.0 MITF PMEL
39 lentigo maligna melanoma 10.0 MITF S100B
40 ganglioglioma 10.0 BRAF S100B
41 acanthosis nigricans 9.9
42 breast cancer 9.9
43 colorectal cancer 9.9
44 multiple sclerosis 9.9
45 pilomatrixoma 9.9
46 coffin-siris syndrome 1 9.9
47 neurofibromatosis, type i 9.9
48 neutrophil migration 9.9
49 parkinson disease, late-onset 9.9
50 pectus excavatum 9.9

Graphical network of the top 20 diseases related to Melanoma in Congenital Melanocytic Nevus:



Diseases related to Melanoma in Congenital Melanocytic Nevus

Symptoms & Phenotypes for Melanoma in Congenital Melanocytic Nevus

MGI Mouse Phenotypes related to Melanoma in Congenital Melanocytic Nevus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.72 BRAF MITF NRAS PMEL S100B
2 integument MP:0010771 9.65 BRAF MITF NRAS PMEL S100B
3 normal MP:0002873 9.46 BRAF MITF NRAS S100B
4 pigmentation MP:0001186 9.26 BRAF MITF NRAS PMEL
5 vision/eye MP:0005391 8.92 BRAF MITF NRAS PMEL

Drugs & Therapeutics for Melanoma in Congenital Melanocytic Nevus

Drugs for Melanoma in Congenital Melanocytic Nevus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 640)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
2
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
3
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
4
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
9
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 70789204 6442177
10
Pembrolizumab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 1374853-91-4
11
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
12
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
13
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
14
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
15
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
16
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
17
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
18
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 5005498 11431660 5330286
19
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 110942-02-4, 85898-30-2
20
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
21
Remifentanil Approved Phase 4 132875-61-7 60815
22
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
23
Nevirapine Approved Phase 4 129618-40-2 4463
24
Lopinavir Approved Phase 4 192725-17-0 92727
25
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
26
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
27
Etanercept Approved, Investigational Phase 4 185243-69-0
28
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
29
Pasireotide Approved Phase 4,Phase 2,Phase 1 396091-73-9 9941444
30
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
31
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
32
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
33
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
34
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
35
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
36
Ceritinib Approved Phase 4,Phase 2 1032900-25-6
37
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
38
Olaparib Approved Phase 4 763113-22-0 23725625
39
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
40
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-88-6, 585-86-4 493591
41
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2 231277-92-2, 388082-78-8 208908 9941095
42 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
46 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
49 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2036)
# Name Status NCT ID Phase Drugs
1 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
4 Scalp Nerve Block on Emergence Agitation Completed NCT02428283 Phase 4 Ropivacaine;Remifentanil;Sevoflurane
5 Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) Completed NCT01637558 Phase 4 8 hourly LPV/r during TB treatment;Nevirapine;Lopinavir/Ritonavir
6 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
7 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
8 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
9 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
10 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
11 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
12 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
13 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
14 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
15 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
16 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
17 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
18 Safety of Rabivax-S for Pre-exposure Prophylaxis Enrolling by invitation NCT03741270 Phase 4
19 Non-specific Effects of Rabies Vaccine Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
20 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
21 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
22 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
23 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
24 Neoadjuvant L19IL2/L19TNF- Pivotal Study Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
25 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
26 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
27 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
28 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
29 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
30 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
31 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
32 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
33 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
34 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
35 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
36 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
37 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
38 Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion Completed NCT00926952 Phase 3 Methylaminolevulinate (Metvix, Metvixia)
39 A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies Completed NCT02829775 Phase 2, Phase 3 Pegylated Interferon Alfa-2a;Recombinant Interferon Alfa 2a
40 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
41 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
42 A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma Completed NCT01667419 Phase 3 Vemurafenib;Placebo
43 Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma Completed NCT01597908 Phase 3 Dabrafenib;Vemurafenib;Trametinib
44 A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Completed NCT01584648 Phase 3 dabrafenib;dabrafenib plus trametinib placebo;Trametinib
45 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 3
46 An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma Completed NCT01368276 Phase 3 Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
47 Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Completed NCT01359956 Phase 3 Dacarbazine;Fotemustine;Interferon Alfa-2b
48 A Study of Vemurafenib in Participants With Metastatic Melanoma Completed NCT01307397 Phase 3 Vemurafenib
49 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3 Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years
50 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy

Search NIH Clinical Center for Melanoma in Congenital Melanocytic Nevus

Genetic Tests for Melanoma in Congenital Melanocytic Nevus

Anatomical Context for Melanoma in Congenital Melanocytic Nevus

MalaCards organs/tissues related to Melanoma in Congenital Melanocytic Nevus:

42
Skin, Brain, Lymph Node, Lung, Liver, T Cells, Kidney

Publications for Melanoma in Congenital Melanocytic Nevus

Articles related to Melanoma in Congenital Melanocytic Nevus:

(show top 50) (show all 791)
# Title Authors Year
1
Regression of benign melanocytic nevi ipilimumab-induced in an adult patient affected by metastatic melanoma: is it a sign of response to therapy? ( 31104465 )
2019
2
Lethal melanoma in a two-year-old child with multiple congenital melanocytic nevi. ( 30560815 )
2019
3
Multiple melanocytic nevi restricted to mycosis fungoides patches in pediatric and young-adult patients. The potential role of local immunosuppression. ( 30656726 )
2019
4
Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review. ( 30032412 )
2019
5
Vitiligo and melanocytic nevi: New findings in Coffin-Siris syndrome associated with ARID1 germline mutation. ( 30581937 )
2019
6
Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa. ( 30555879 )
2019
7
Neurocutaneous Melanosis in Association With Large Congenital Melanocytic Nevi in Children: A Report of 2 Cases With Clinical, Radiological, and Pathogenetic Evaluation. ( 30792691 )
2019
8
Pluripotency markers are differentially induced by IGF1 and bFGF in cells from patients' lesions of large/giant congenital melanocytic nevi. ( 30675361 )
2019
9
Molecular Genomic Profiling of Melanocytic Nevi. ( 30772300 )
2019
10
Massively Parallel Sequencing Analysis of Benign Melanocytic Nevi. ( 30791119 )
2019
11
Combination laser therapy as a non-surgical method for treating congenital melanocytic nevi from cosmetically sensitive locations on the body. ( 30820775 )
2019
12
Evolution of congenital melanocytic nevi toward benignity: A case series. ( 30840320 )
2019
13
Large-Giant Congenital Melanocytic Nevi: Moving Beyond NRAS Mutations. ( 30904080 )
2019
14
Predictors of Health-related Quality of Life and Psychological Adjustment in Children and Adolescents With Congenital Melanocytic Nevi: Analysis of Parent Reports. ( 30916755 )
2019
15
Cosmetically Challenging Congenital Melanocytic Nevi. ( 30973837 )
2019
16
Distinguishing melanocytic nevi from melanomas using static and dynamic infrared thermal imaging. ( 30974494 )
2019
17
Dermatoscopic evaluation of melanocytic nevi under laser therapy. ( 31020727 )
2019
18
Local inhibition of MEK/AKT prevents cellular growth in human congenital melanocytic nevi. ( 31059696 )
2019
19
CDK16/PCTK1/PCTAIRE1 is highly expressed in melanomas but not in melanocytic nevi or sarcomas. ( 31106900 )
2019
20
Melanoma and melanocytic nevi in pediatric patients: a single institution experience. ( 28290622 )
2019
21
Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases. ( 29128957 )
2019
22
Density and distribution of acral melanocytic nevi and acral melanomas on the plantar surface of the foot. ( 30055202 )
2019
23
Long-term outcomes of laser treatment for congenital melanocytic nevi. ( 30227194 )
2019
24
Tyrosinase and nestin immunohistochemical expression in melanocytic nevi as a histopathologic pattern to trace melanocyte differentiation and nevogenesis. ( 30232588 )
2019
25
Comparison of treatment options for small to medium congenital melanocytic nevi: A retrospective review of 119 cases. ( 30375012 )
2019
26
Dermoscopic evaluation of melanocytic nevi changes after photo-epilation techniques: a prospective study. ( 30520186 )
2019
27
Common Neonatal Skin Lesions: Melanocytic Nevi, Pigment Alterations, and Nonmelanocytic Nevi. ( 30653639 )
2019
28
Resection of melanocytic nevi as a potential treatment of anti-NMDAR encephalitis patients without tumor: report of three cases. ( 29128985 )
2018
29
Regression of multiple melanocytic nevi associated with nivolumab treatment for metastatic melanoma. ( 30536371 )
2018
30
Pushing and loss of elastic fibers are highly specific for melanoma and rare in melanocytic nevi. ( 30547366 )
2018
31
Germline BRCA1-associated protein 1 mutation presenting as BAP1 inactivated melanocytic nevi in a child of a father with fatal paraganglioma. ( 29974497 )
2018
32
Eruptive melanocytic nevi in a patient with toxic epidermal necrolysis-like cutaneous lupus. ( 29301474 )
2018
33
The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas. ( 27490764 )
2018
34
Serial excision with power-stretching of the skin in giant melanocytic nevi therapy. ( 29242149 )
2018
35
BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi. ( 29332123 )
2018
36
Histological features and outcome of inverted type-A melanocytic nevi. ( 29341232 )
2018
37
Reduced H3K27me3 Expression is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules. ( 29369061 )
2018
38
An alternative strategy treated giant congenital melanocytic nevi with epidermis and superficial dermis of the lesions. ( 29369208 )
2018
39
Nevoid Basal Cell Carcinomata Mimicking Melanocytic Nevi: Case Report. ( 29383948 )
2018
40
CKS1 expression in melanocytic nevi and melanoma. ( 29423113 )
2018
41
Multiple perineuriomatous melanocytic nevi. ( 29468709 )
2018
42
Small Dysplastic Congenital Melanocytic Nevi in Childhood as Possible Melanoma Imitators. ( 29484015 )
2018
43
Giant Congenital Melanocytic Nevi: An Update and Emerging Therapies. ( 29515391 )
2018
44
An unusual presentation of multiple congenital melanocytic nevi with a whole-body distribution. ( 29567913 )
2018
45
Sun-Protection Behavior, Pubertal Development and Menarche: Factors Influencing the Melanocytic Nevi Development-The Results of an Observational Study of 1,512 Children. ( 29614272 )
2018
46
Two cases of discrete adenoid pseudogland formation within benign intradermal melanocytic nevi. ( 29624714 )
2018
47
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features. ( 29653212 )
2018
48
Therapeutic effects of targeting RAS-ERK signaling in giant congenital melanocytic nevi. ( 29736211 )
2018
49
Dermoscopic changes in melanocytic nevi covered with both opaque tape and sunscreen cream during narrowband ultraviolet B therapy. ( 29785332 )
2018
50
Detection of a MicroRNA molecular signature of ultraviolet radiation in the superficial regions of melanocytic nevi on sun-exposed skin. ( 29955145 )
2018

Variations for Melanoma in Congenital Melanocytic Nevus

Expression for Melanoma in Congenital Melanocytic Nevus

Search GEO for disease gene expression data for Melanoma in Congenital Melanocytic Nevus.

Pathways for Melanoma in Congenital Melanocytic Nevus

Pathways related to Melanoma in Congenital Melanocytic Nevus according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.4 BRAF MITF NRAS
2
Show member pathways
12.22 BRAF MITF NRAS
3
Show member pathways
12.18 BRAF MITF NRAS
4
Show member pathways
11.72 BRAF NRAS
5
Show member pathways
11.7 BRAF NRAS
6 11.62 BRAF NRAS
7 11.6 BRAF NRAS
8 11.58 BRAF NRAS
9
Show member pathways
11.56 NRAS S100B
10
Show member pathways
11.53 BRAF MITF NRAS
11
Show member pathways
11.43 BRAF NRAS
12 11.34 BRAF NRAS
13 11.27 MITF NRAS
14
Show member pathways
11.25 BRAF NRAS
15 11.15 BRAF NRAS
16
Show member pathways
11.05 BRAF MITF NRAS
17 10.89 BRAF NRAS
18 10.69 BRAF NRAS

GO Terms for Melanoma in Congenital Melanocytic Nevus

Biological processes related to Melanoma in Congenital Melanocytic Nevus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 long-term synaptic potentiation GO:0060291 8.62 BRAF S100B

Sources for Melanoma in Congenital Melanocytic Nevus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....